# HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

> **NCT02856126** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 214 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **PROCEDURE:** Transarterial chemoembolization
- **DRUG:** TACE regimen
- **DRUG:** HAIC Regimen
- **DRUG:** Oral Sorafenib

## Key facts

- **NCT ID:** NCT02856126
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2020-10
- **Final completion:** 2024-07
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856126, "HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02856126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*